In vivo modulation of LPS-induced alterations in brain and peripheral cytokines and HPA axis activity by cannabinoids

Journal of Neuroimmunology

Volumn 181, Issue 1-2, 2006, Pages 57-67

  Roche, Michelle ^a   Diamond, Michael ^a   Kelly, John P ^a   Finn, David P ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Corticosterone; HU210; IL 1 ; SR141716A; SR144528; TNF

Indexed keywords

5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; BACTERIUM LIPOPOLYSACCHARIDE; CANNABINOID RECEPTOR; CORTICOSTERONE; CYTOKINE; DEXANABINOL; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; RIMONABANT; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENDOCRINE FUNCTION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOPHARMACOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; INFLAMMATORY DISEASE; LYMPHOCYTE COUNT; MALE; MONOTHERAPY; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; RAT;

ANIMALS; BORNANES; CORTICOSTERONE; DRUG INTERACTIONS; ENCEPHALITIS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; LYMPHOCYTE COUNT; MALE; NEUROIMMUNOMODULATION; NEUROPROTECTIVE AGENTS; PIPERIDINES; PITUITARY-ADRENAL SYSTEM; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; TETRAHYDROCANNABINOL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33847127870     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2006.08.001     Document Type: Article

References (65)

1. Beishuizen A., and Thijs L.G. Endotoxin and the hypothalamo-pituitary-adrenal (HPA) axis. J. Endotoxin Res. 9 (2003) 3-24
2. Bethin K.E., Vogt S.K., and Muglia L.J. Interleukin-6 is an essential, corticotropin-releasing hormone-independent stimulator of the adrenal axis during immune system activation. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 9317-9322
3. Bik W., Wolinska-Witort E., Chmielowska M., Baranowska-Bik A., Rusiecka-Kuczalek E., and Baranowska B. Vasoactive intestinal peptide can modulate immune and endocrine responses during lipopolysaccharide-induced acute inflammation. Neuroimmunomodulation 11 (2004) 358-364
4. Bouaboula M., Rinaldi M., Carayon P., Carillon C., Delpech B., Shire D., Le Fur G., and Casellas P. Cannabinoid-receptor expression in human leukocytes. Eur. J. Biochem. 214 (1993) 173-180
5. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
6. Cabranes A., Venderova K., de Lago E., Fezza F., Sanchez A., Mestre L., Valenti M., Garcia-Merino A., Ramos J.A., Di Marzo V., and Fernandez-Ruiz J. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. Neurobiol. Dis. 20 (2005) 207-217
7. Chang Y.H., Lee S.T., and Lin W.W. Effects of cannabinoids on LPS-stimulated inflammatory mediator release from macrophages: involvement of eicosanoids. J. Cell. Biochem. 81 (2001) 715-723
8. Cheer J.F., Kendall D.A., and Marsden C.A. Cannabinoid receptors and reward in the rat: a conditioned place preference study. Psychopharmacology 151 (2000) 25-30
9. Costa B., Trovato A.E., Colleoni M., Giagnoni G., Zarini E., and Croci T. Effect of the cannabinoid CB1 receptor antagonist, SR141716, on nociceptive response and nerve demyelination in rodents with chronic constriction injury of the sciatic nerve. Pain 116 (2005) 52-61
10. Cristino L., de Petrocellis L., Pryce G., Baker D., Guglielmotti V., and Di Marzo V. Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience 139 (2006) 1405-1415
11. Croci T., Landi M., Galzin A.M., and Marini P. Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents. Br. J. Pharmacol. 140 (2003) 115-122
12. Di Marzo V., Bisogno T., De Petrocellis L., Melck D., Orlando P., Wagner J.A., and Kunos G. Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur. J. Biochem. 264 (1999) 258-267
13. Di Marzo V., Bifulco M., and De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat. Rev., Drug Discov. 3 (2004) 771-784
14. Facchinetti F., Del Giudice E., Furegato S., Passarotto M., and Leon A. Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide. Glia 41 (2003) 161-168
15. Finn D.P., and Chapman V. Cannabinoids as analgesic agents: evidence from in vivo studies. Curr. Neuropharmacol. 2 (2004) 75-89
16. Finn D.P., Beckett S.R., Roe C.H., Madjd A., Fone K.C., Kendall D.A., Marsden C.A., and Chapman V. Effects of coadministration of cannabinoids and morphine on nociceptive behaviour, brain monoamines and HPA axis activity in a rat model of persistent pain. Eur. J. Neurosci. 19 (2004) 678-686
17. Galiegue S., Mary S., Marchand J., Dussossoy D., Carriere D., Carayon P., Bouaboula M., Shire D., Le Fur G., and Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 232 (1995) 54-61
18. Gallily R., Yamin A., Waksmann Y., Ovadia H., Weidenfeld J., Bar-Joseph A., Biegon A., Mechoulam R., and Shohami E. Protection against septic shock and suppression of tumor necrosis factor alpha and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid. J. Pharmacol. Exp. Ther. 283 (1997) 918-924
19. Germain N., Boichot E., Advenier C., Berdyshev E.V., and Lagente V. Effect of the cannabinoid receptor ligand, WIN 55,212-2, on superoxide anion and TNF-alpha production by human mononuclear cells. Int. Immunopharmacol. 2 (2002) 537-543
20. Grotenhermen F. Cannabinoids. Curr. Drug Targets CNS Neurol. Disord. 4 (2005) 507-530
21. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., and Rice K.C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 1932-1936
22. Jackson S.J., Diemel L.T., Pryce G., and Baker D. Cannabinoids and neuroprotection in CNS inflammatory disease. J. Neurol. Sci. 233 (2005) 21-25
23. Kaplan B.L., Rockwell C.E., and Kaminski N.E. Evidence for cannabinoid receptor-dependent and -independent mechanisms of action in leukocytes. J. Pharmacol. Exp Ther. 306 (2003) 1077-1085
24. Klegeris A., Bissonnette C.J., and McGeer P.L. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br. J. Pharmacol. 139 (2003) 775-786
25. Klein T.W. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat. Rev., Immunol. 5 (2005) 400-411
26. Klein T.W., Kawakami Y., Newton C., and Friedman H. Marijuana components suppress induction and cytolytic function of murine cytotoxic T cells in vitro and in vivo. J. Toxicol. Environ. Health 32 (1991) 465-477
27. Lenczowski M.J., Van Dam A.M., Poole S., Larrick J.W., and Tilders F.J. Role of circulating endotoxin and interleukin-6 in the ACTH and corticosterone response to intraperitoneal LPS. Am. J. Physiol. 273 (1997) R1870-R1877
28. Maccarrone M., De Petrocellis L., Bari M., Fezza F., Salvati S., Di Marzo V., and Finazzi-Agro A. Lipopolysaccharide downregulates fatty acid amide hydrolase expression and increases anandamide levels in human peripheral lymphocytes. Arch. Biochem. Biophys. 393 (2001) 321-328
29. Maccarrone M., Bari M., Battista N., and Finazzi-Agro A. Endocannabinoid degradation, endotoxic shock and inflammation. Curr. Drug Targets Inflamm. Allergy 1 (2002) 53-63
30. Martin-Calderon J.L., Munoz R.M., Villanua M.A., del Arco I., Moreno J.L., de Fonseca F.R., and Navarro M. Characterization of the acute endocrine actions of (-)-11-hydroxy-delta8-tetrahydrocannabinol-dimethylheptyl (HU-210), a potent synthetic cannabinoid in rats. Eur. J. Pharmacol. 344 (1998) 77-86
31. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., and Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (1990) 561-564
32. Mazzari S., Canella R., Petrelli L., Marcolongo G., and Leon A. N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur. J. Pharmacol. 300 (1996) 227-236
33. Mazzocchi G., Gottardo G., and Nussdorfer G.G. A local immuno-endocrine interaction may mediate rat adrenal glucocorticoid response to bacterial endotoxins. Life Sci. 62 (1998) 1783-1787
34. McKallip R.J., Lombard C., Martin B.R., Nagarkatti M., and Nagarkatti P.S. Delta(9)-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo. J. Pharmacol. Exp. Ther. 302 (2002) 451-465
35. Mechoulam R. Discovery of endocannabinoids and some random thoughts on their possible roles in neuroprotection and aggression. Prostaglandins Leukot. Essent. Fat. Acids 66 (2002) 93-99
36. Mechoulam R., Fride E., and Di Marzo V. Endocannabinoids. Eur. J. Pharmacol. 359 (1998) 1-18
37. Mechoulam R., Panikashvili D., and Shohami E. Cannabinoids and brain injury: therapeutic implications. Trends Mol. Med. 8 (2002) 58-61
38. Mestre L., Correa F., Arevalo-Martin A., Molina-Holgado E., Valenti M., Ortar G., Di Marzo V., and Guaza C. Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. J. Neurochem. 92 (2005) 1327-1339
39. Molina-Holgado F., Molina-Holgado E., and Guaza C. The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptor-mediated pathway. FEBS Lett. 433 (1998) 139-142
40. Molina-Holgado F., Pinteaux E., Moore J.D., Molina-Holgado E., Guaza C., Gibson R.M., and Rothwell N.J. Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J. Neurosci. 23 (2003) 6470-6474
41. Munro S., Thomas K.L., and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (1993) 61-65
42. Ortega-Gutierrez S., Molina-Holgado E., Arevalo-Martin A., Correa F., Viso A., Lopez-Rodriguez M.L., Di Marzo V., and Guaza C. Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis. Faseb J. 19 (2005) 1338-1340
43. Ortega-Gutierrez S., Molina-Holgado E., and Guaza C. Effect of anandamide uptake inhibition in the production of nitric oxide and in the release of cytokines in astrocyte cultures. Glia 52 (2005) 163-168
44. Panikashvili D., Simeonidou C., Ben-Shabat S., Hanus L., Breuer A., Mechoulam R., and Shohami E. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413 (2001) 527-531
45. Panikashvili D., Shein N.A., Mechoulam R., Trembovler V., Kohen R., Alexandrovich A., and Shohami E. The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol. Dis. 22 (2006) 257-264
46. Puffenbarger R.A., Boothe A.C., and Cabral G.A. Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia 29 (2000) 58-69
47. Rivier C., Chizzonite R., and Vale W. In the mouse, the activation of the hypothalamic-pituitary-adrenal axis by a lipopolysaccharide (endotoxin) is mediated through interleukin-1. Endocrinology 125 (1989) 2800-2805
48. Roche M., Diamond M., Lonergan I., Keeney G., Kelly J.P., and Finn D.P. The effects of acute lipopolysaccaride injection on levels of pro- and anti-inflammatory cytokines in discrete rat brain regions. J. Psychopharmacol. 19 (2005) A37
49. Rockwell C.E., Snider N.T., Thompson J.T., Vanden Heuvel J.P., and Kaminski N.E. Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator activated receptor{gamma} independently of cannabinoid receptors 1 and 2. Mol. Pharmacol. 70 1 (2006) 101-111
50. Rodriguez de Fonseca F., Rubio P., Menzaghi F., Merlo-Pich E., Rivier J., Koob G.F., and Navarro M. Corticotropin-releasing factor (CRF) antagonist [d-Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats. J. Pharmacol. Exp. Ther. 276 (1996) 56-64
51. Roth M.D., Baldwin G.C., and Tashkin D.P. Effects of delta-9-tetrahydrocannabinol on human immune function and host defense. Chem. Phys. Lipids 121 (2002) 229-239
52. Sacerdote P., Massi P., Panerai A.E., and Parolaro D. In vivo and in vitro treatment with the synthetic cannabinoid CP55, 940 decreases the in vitro migration of macrophages in the rat: involvement of both CB1 and CB2 receptors. J. Neuroimmunol. 109 (2000) 155-163
53. Schwarz H., Blanco F.J., and Lotz M. Anadamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis. J. Neuroimmunol. 55 (1994) 107-115
54. Smith S.R., Terminelli C., and Denhardt G. Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice. J. Pharmacol. Exp. Ther. 293 (2000) 136-150
55. Smith S.R., Denhardt G., and Terminelli C. The anti-inflammatory activities of cannabinoid receptor ligands in mouse peritonitis models. Eur. J. Pharmacol. 432 (2001) 107-119
56. Smith S.R., Terminelli C., and Denhardt G. Modulation of cytokine responses in Corynebacterium parvum-primed endotoxemic mice by centrally administered cannabinoid ligands. Eur. J. Pharmacol. 425 (2001) 73-83
57. Sundar S.K., Cierpial M.A., Kilts C., Ritchie J.C., and Weiss J.M. Brain IL-1-induced immunosuppression occurs through activation of both pituitary-adrenal axis and sympathetic nervous system by corticotropin-releasing factor. J. Neurosci. 10 (1990) 3701-3706
58. Turrin N.P., Gayle D., Ilyin S.E., Flynn M.C., Langhans W., Schwartz G.J., and Plata-Salaman C.R. Pro-inflammatory and anti-inflammatory cytokine mRNA induction in the periphery and brain following intraperitoneal administration of bacterial lipopolysaccharide. Brain Res. Bull. 54 (2001) 443-453
59. Waksman Y., Olson J.M., Carlisle S.J., and Cabral G.A. The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. J. Pharmacol. Exp. Ther. 288 (1999) 1357-1366
60. Walter L., and Stella N. Cannabinoids and neuroinflammation. Br. J. Pharmacol. 141 (2004) 775-785
61. Walter L., Franklin A., Witting A., Wade C., Xie Y., Kunos G., Mackie K., and Stella N. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J. Neurosci. 23 (2003) 1398-1405
62. Watkins L.R., Maier S.F., and Goehler L.E. Cytokine-to-brain communication: a review and analysis of alternative mechanisms. Life Sci. 57 (1995) 1011-1026
63. Weidenfeld J., Feldman S., and Mechoulam R. Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat. Neuroendocrinology 59 (1994) 110-112
64. Wiegers G.J., Croiset G., Reul J.M., Holsboer F., and de Kloet E.R. Differential effects of corticosteroids on rat peripheral blood T-lymphocyte mitogenesis in vivo and in vitro. Am. J. Physiol. 265 (1993) E825-E830
65. Zygmunt P.M., Petersson J., Andersson D.A., Chuang H., Sorgard M., Di Marzo V., Julius D., and Hogestatt E.D. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400 (1999) 452-457